Cosmo's GI Genius(TM) Proven Effective In Colonoscopy, Says Major Study In 'The Lancet'

Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43), is thrilled to share that a groundbreaking study featuring its GI Genius™ intelligent endoscopy system has been published in The Lancet. The study, titled “Polyp Detection with Colonoscopy Assisted by the GI Genius™ AI Module Compared with Standard Colonoscopy in Routine Practice (COLO-DETECT): A Multicentre, Open-Label, Parallel-Arm, Randomised Controlled Trial,” marks a significant leap forward in colorectal cancer screening and detection.

Conducted by a distinguished team including Alexander Seager, MSc, Prof. Linda Sharp, PhD, and Laura J. Neilson, MD, among others, the COLO-DETECT study underscores the GI Genius™ system's efficacy in improving polyp detection rates. The trial, which involved multiple centers and an open-label design, revealed that GI Genius™ enhances the detection of colorectal adenomas by an additional 8.3% compared to traditional colonoscopy methods, potentially lowering the risk of colorectal cancer.

Gio Di Napoli, CEO of Cosmo Pharmaceuticals, “This publication is a major milestone not only for Cosmo Pharmaceuticals but also for the global medical community. The GI Genius™ system, exclusively distributed by Medtronic globally, continues to prove its value in routine clinical practice, by assisting in providing better outcomes for patients undergoing colonoscopy. We are proud to be at the forefront of innovation in AI-assisted healthcare, and this study reinforces our commitment to advancing patient care through cutting-edge technology.”

The study highlights the benefits of incorporating artificial intelligence into standard clinical practice to boost the precision and effectiveness of colorectal cancer screening. Given that colorectal cancer is a major cause of cancer-related mortality around the globe, detecting precancerous polyps more effectively is crucial for timely intervention and prevention.

Cosmo Pharmaceuticals is dedicated to advancing the medical field with pioneering solutions like GI Genius™, which represent the cutting edge of AI in healthcare. The company is committed to collaborating with its distribution partner, Medtronic, to ensure that this transformative technology is available to healthcare providers worldwide.